International
A trial has shown that a new drug, Ivarmacitinib, is safe and effective for treating moderate to severe eczema in adults and teens. Eczema, or atopic dermatitis, affects around 10-20% of children and 2-10% of adults, and treating the more severe forms of the disease has remained challenging. The new drug works on a pathway which is central to inflammation in atopic dermatitis, and the trial showed that more patients taking the drug improved on a scale of eczema severity, compared to placebo. The authors say the results support the potential of ivarmacitinib as a new therapeutic option.
Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.
Sign In
